Novartis AG had reason to cheer in May when an appeals court upheld the validity of two patents covering its Exelon Patch (rivastigmine) for Alzheimer’s disease. But the victory was short-lived. Four months later, a panel of administrative judges at the US Patent and Trademark Office concluded several of the patent claims were unpatentable.
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.
More from Archive
More from In Vivo
• By
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
• By
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.